title: [Effect of administration of blood products on the course of tetanus antibody concentration in immuno-incompetent patients].
abstract: OBJECTIVE
  Collecting of data for immunoprophylaxis of tetanus in immunodeficient patients via administration of blood products.
  
  
  METHODS
  Prospective single case studies.
  
  
  METHODS
  Clinical therapy in a department of hematology with continuous determination of tetanus antibody concentrations in patients' sera and administered blood products with an enzyme immunoassay.
  
  
  METHODS
  3 patients with acute myeloid leukemia (FAB classifications M1, M3, M4).
  
  
  METHODS
  Regular administration of blood products due to clinical therapy.
  
  
  RESULTS
  After administration of about 4,000 IU tetanus antitoxin i.v., serum concentration is increasing by 1 IU/ml. Half life in serum amounts to 7 days. Protection lasts therefore up to 6 weeks.
  
  
  CONCLUSIONS
  Immunodeficient patients may receive a medium-term effective protection against tetanus after selection of suitable blood products. This method is interesting also for prophylaxis of postoperative tetanus in immunocompetent patients.
authors.affiliation: Abteilung für Hygiene, Universität Mainz, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Pietsch
authors.forename: S
authors.initials: S
authors.lastname: Töre
authors.forename: K H
authors.initials: KH
authors.lastname: Schütt
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D016913:Blood Component Transfusion; D003017:Clostridium tetani / Q000276:immunology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D015470:Leukemia, Myeloid, Acute / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000276:immunology* / Q000517:prevention & control; D011446:Prospective Studies; D013742:Tetanus / Q000276:immunology* / Q000517:prevention & control; D013743:Tetanus Antitoxin / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D013743:Tetanus Antitoxin
vernacular_title: Einfluss der Verabreichung von Blutprodukten auf den Verlauf der Tetanus-Antikörperkonzentration bei immuninkompetenten Patienten.